무좀 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 제품 유형별, 약물 종류별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Athlete´s Foot Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Product Type, By Drug Class, By Distribution Channel, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,197,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,574,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,017,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계 무좀 치료제 시장은 2024년에 9억 6,534만 달러로 평가되며, 2030년에는 13억 1,026만 달러에 달할 것으로 예상되며, 예측 기간 동안 5.22%의 CAGR로 성장할 것으로 예상됩니다.

무좀 치료제 시장에 초점을 맞춘 이 시장은 주로 발에 가려움증, 발적, 피부 비늘을 유발하는 광범위한 곰팡이 감염을 다루고 있습니다. 무좀이 삶의 질에 미치는 영향에 대한 인식이 높아지면서 신속하고 효과적인 치료 옵션에 대한 수요가 증가하고 있습니다. 무좀 환자는 운동선수, 면역력이 저하된 사람, 체육관이나 수영장과 같이 습한 환경에 자주 노출되는 사람 등이 포함됩니다. 전 세계 인구의 약 15%가 곰팡이 감염을 앓고 있는 만큼, 접근성이 좋고 효과적인 치료법의 필요성이 대두되고 있습니다. 시중에는 시판되는 외용제부터 처방전이 필요한 강력한 약물에 이르기까지 다양한 치료 옵션이 있습니다. 제약사들은 새로운 치료법을 도입하고 약물전달 메커니즘을 개선하기 위해 연구개발에 지속적으로 투자하고 있습니다. 현재 북미와 유럽이 의료 인프라와 인지도 향상으로 선두를 달리고 있으며, 아시아태평양과 라틴아메리카 지역은 의료 접근성 향상과 개인 위생에 대한 인식이 높아지면서 성장이 가속화되고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	9억 6,534만 달러
시장 규모 : 2030년	13억 1,026만 달러
CAGR : 2025-2030년	5.22%
급성장 부문	스프레이
최대 시장	북미

주요 시장 촉진요인

무좀 유행

주요 시장 과제

항진균제에 대한 내성

주요 시장 동향

병용요법

목차

제1장 제품 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 무좀 치료제 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별(지간형 감염증, 모카신형 감염증, 궤양성 감염증)
  • 제품 유형별(외용 크림·연고, 스프레이, 로션, 경구제, 기타)
  • 약물 종류별(항진균제, 코르티코스테로이드, 항생제, 기타)
  • 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
  • 지역별
  • 기업별(2024년)
• 시장 맵
  • 유형별
  • 제품 유형별
  • 약물 종류별
  • 유통 채널별
  • 지역별

제5장 아시아태평양의 무좀 치료제 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 제품 유형별
  • 약물 종류별
  • 유통 채널별
  • 국가별
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제6장 유럽의 무좀 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제7장 북미의 무좀 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제8장 남미의 무좀 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제9장 중동 및 아프리카의 무좀 치료제 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제10장 시장 역학

• 성장 촉진요인
• 과제

제11장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병

제12장 세계의 무좀 치료제 시장 : SWOT 분석

제13장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제14장 경쟁 구도

• Novartis AG
• Vibcare Pharma Pvt. Ltd.
• Bayer AG
• Taro Pharmaceutical Industries Ltd
• GLENMARK PHARMACEUTICALS LTD
• Abigail Healthcare Pharmaceutical
• ANI Pharmaceuticals, Inc.
• Perrigo Company plc
• Xiromed
• Sebela Pharmaceuticals

제15장 전략적 제안

제16장 조사 회사 소개 및 면책사항

ksm

영문 목차

영문목차

The Global Athlete's Foot Drugs Market was valued at USD 965.34 Million in 2024 and is projected to reach USD 1310.26 Million by 2030, growing at a CAGR of 5.22% during the forecast period. This market, which focuses on pharmaceutical treatments for athlete's foot (tinea pedis), addresses a widespread fungal infection that causes itching, redness, and skin scaling, primarily on the feet. Increased awareness of the condition's impact on quality of life has contributed to a growing demand for rapid and effective treatment options. Affected populations include athletes, individuals with compromised immunity, and those frequently exposed to moist environments such as communal gyms or swimming areas. With approximately 15% of the global population experiencing fungal infections, the need for accessible and efficacious therapies is apparent. The market includes a variety of treatment options, ranging from over-the-counter topical formulations to prescription-strength medications. Pharmaceutical companies continue to invest in research and development to introduce novel therapies and improve drug delivery mechanisms. While North America and Europe currently lead due to better healthcare infrastructure and awareness, the Asia-Pacific and Latin American regions are experiencing accelerated growth driven by improving healthcare access and rising personal hygiene consciousness.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 965.34 Million
Market Size 2030	USD 1310.26 Million
CAGR 2025-2030	5.22%
Fastest Growing Segment	Sprays
Largest Market	North America

Key Market Drivers

Prevalence of Athlete's Foot

The widespread occurrence of athlete's foot continues to be a primary factor fueling market expansion. This contagious fungal condition is frequently encountered in shared public environments, such as locker rooms and pools, and is especially prevalent among athletes and workers exposed to persistent moisture. The high transmission rate and discomfort associated with the condition compel affected individuals to seek pharmaceutical interventions. As the global incidence of tinea pedis remains elevated, the demand for antifungal treatments sustains the growth momentum of the athlete's foot drug market.

Key Market Challenges

Resistance to Antifungal Medications

A significant challenge facing the Global Athlete's Foot Drugs Market is the increasing resistance to antifungal medications. Repeated and sometimes inappropriate use of antifungal agents can result in reduced drug efficacy as fungal strains adapt and become more resilient. This not only compromises treatment outcomes but also increases the risk of prolonged infections and patient dissatisfaction. Continued use of ineffective treatments due to resistance can diminish consumer confidence in available products and hinder market progress. Addressing this challenge requires the development of innovative therapies with broader and more durable efficacy profiles.

Key Market Trends

Combination Therapies

Combination therapies have gained traction as a promising approach to managing athlete's foot. These treatments utilize multiple antifungal agents with distinct mechanisms of action to enhance therapeutic outcomes and reduce the risk of resistance. Particularly effective in persistent or recurring cases, combination therapies have shown faster symptom relief and higher eradication rates. Their adaptability allows for personalized treatment strategies tailored to the severity of individual cases. Pharmaceutical companies have responded by developing diverse combination formulations, expanding therapeutic options and reinforcing market growth through innovation and improved patient satisfaction.

Key Market Players

• Novartis AG
• Vibcare Pharma Pvt. Ltd.
• Bayer AG
• Taro Pharmaceutical Industries Ltd
• Glenmark Pharmaceuticals Ltd.
• Abigail Healthcare Pharmaceutical
• ANI Pharmaceuticals, Inc.
• Perrigo Company plc
• Xiromed
• Sebela Pharmaceuticals

Report Scope:

In this report, the Global Athlete's Foot Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Athlete's Foot Drugs Market, By Type:

• Toe Web Infection
• Moccasin-type Infection
• Ulcerative Infection

Athlete's Foot Drugs Market, By Product Type:

• Topical Creams and Ointments
• Sprays
• Lotions
• Oral Medications
• Others

Athlete's Foot Drugs Market, By Drug Class:

• Antifungal Agents
• Corticosteroid
• Antibiotics
• Others

Athlete's Foot Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Athlete's Foot Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Athlete's Foot Drugs Market.

Available Customizations:

Global Athlete's Foot Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Athlete's Foot Drugs Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Toe Web Infection, Moccasin-type Infection, Ulcerative Infection)
  • 4.2.2. By Product Type (Topical Creams and Ointments, Sprays, Lotions, Oral Medications, Others)
  • 4.2.3. By Drug Class (Antifungal Agents, Corticosteroid, Antibiotics, Others)
  • 4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.5. By Region
  • 4.2.6. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Product Type
  • 4.3.3. By Drug Class
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. Asia Pacific Athlete's Foot Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Product Type
  • 5.2.3. By Drug Class
  • 5.2.4. By Distribution Channel
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Athlete's Foot Drugs Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Product Type
      • 5.3.1.2.3. By Drug Class
      • 5.3.1.2.4. By Distribution Channel
  • 5.3.2. India Athlete's Foot Drugs Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Product Type
      • 5.3.2.2.3. By Drug Class
      • 5.3.2.2.4. By Distribution Channel
  • 5.3.3. Australia Athlete's Foot Drugs Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Product Type
      • 5.3.3.2.3. By Drug Class
      • 5.3.3.2.4. By Distribution Channel
  • 5.3.4. Japan Athlete's Foot Drugs Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Product Type
      • 5.3.4.2.3. By Drug Class
      • 5.3.4.2.4. By Distribution Channel
  • 5.3.5. South Korea Athlete's Foot Drugs Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Product Type
      • 5.3.5.2.3. By Drug Class
      • 5.3.5.2.4. By Distribution Channel

6. Europe Athlete's Foot Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product Type
  • 6.2.3. By Drug Class
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Athlete's Foot Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product Type
      • 6.3.1.2.3. By Drug Class
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Germany Athlete's Foot Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product Type
      • 6.3.2.2.3. By Drug Class
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Spain Athlete's Foot Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product Type
      • 6.3.3.2.3. By Drug Class
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Italy Athlete's Foot Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Product Type
      • 6.3.4.2.3. By Drug Class
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. United Kingdom Athlete's Foot Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Product Type
      • 6.3.5.2.3. By Drug Class
      • 6.3.5.2.4. By Distribution Channel

7. North America Athlete's Foot Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product Type
  • 7.2.3. By Drug Class
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Athlete's Foot Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product Type
      • 7.3.1.2.3. By Drug Class
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Mexico Athlete's Foot Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product Type
      • 7.3.2.2.3. By Drug Class
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Canada Athlete's Foot Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product Type
      • 7.3.3.2.3. By Drug Class
      • 7.3.3.2.4. By Distribution Channel

8. South America Athlete's Foot Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product Type
  • 8.2.3. By Drug Class
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Athlete's Foot Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product Type
      • 8.3.1.2.3. By Drug Class
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Argentina Athlete's Foot Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product Type
      • 8.3.2.2.3. By Drug Class
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Colombia Athlete's Foot Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product Type
      • 8.3.3.2.3. By Drug Class
      • 8.3.3.2.4. By Distribution Channel

9. Middle East and Africa Athlete's Foot Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product Type
  • 9.2.3. By Drug Class
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Athlete's Foot Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product Type
      • 9.3.1.2.3. By Drug Class
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Saudi Arabia Athlete's Foot Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Drug Class
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. UAE Athlete's Foot Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product Type
      • 9.3.3.2.3. By Drug Class
      • 9.3.3.2.4. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Athlete's Foot Drugs Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Novartis AG
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Vibcare Pharma Pvt. Ltd.
• 14.3. Bayer AG
• 14.4. Taro Pharmaceutical Industries Ltd
• 14.5. GLENMARK PHARMACEUTICALS LTD
• 14.6. Abigail Healthcare Pharmaceutical
• 14.7. ANI Pharmaceuticals, Inc.
• 14.8. Perrigo Company plc
• 14.9. Xiromed
• 14.10. Sebela Pharmaceuticals

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료